<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ONDANSETRON- ondansetron hydrochloride injection </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Ondansetron Injection, USP safely and effectively.  See full prescribing information for Ondansetron Injection, USP.<br><br>
Ondansetron Injection, USP for intravenous use<br>

Initial U.S. Approval: 1991</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> (<a href="#be1c1030-f5a0-4094-a8bf-25ced9e8dc70">5.3</a>)   09/2014 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Ondansetron Injection is a 5-HT<span class="Sub">3</span> receptor antagonist indicated: </p>
<ul>
<li>Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of emetogenic cancer chemotherapy. (<a href="#aa47f2bf-0caa-4c04-97ed-c1d09cb0cfeb">1.1</a>)</li>
<li><p class="Highlighta">Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#b95ac3fd-b2b9-40b3-a818-91a9f7c0de31">1.2</a>) </p></li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of emetogenic cancer chemotherapy (<a href="#e72c29fa-abca-419d-bac6-56c488c15704">2.1</a>): </p>
<ul><li>Adults and Pediatric patients (6 months to 18 years): Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes. The first dose should be administered 30 minutes before the start of chemotherapy. Subsequent doses are administered 4 and 8 hours after the first dose.</li></ul>
<p class="Highlighta">Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (<a href="#f3b1aff8-6bf7-4a0b-8385-b577b8f5de15">2.2</a>):  </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta"> <span class="Bold"><span class="Emphasis">Population </span></span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta"><span class="Bold"><span class="Emphasis"> Age </span></span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta"><span class="Bold"><span class="Emphasis"> Dosage of Ondansetron </span></span><span class="Bold"><span class="Emphasis">Injection    </span></span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta"><span class="Bold"><span class="Emphasis"> Intravenous Infusion Rate    </span></span> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">Adults  </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">   &gt; 12 yrs  </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">4 mg x 1  </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">over 2 to 5 min  </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="Highlighta">Pediatrics  </p>
<p class="Highlighta">(&gt; 40 kg)  </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">   1 mo. to 12 yrs  </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">4 mg x 1  </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">over 2 to 5 min  </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="Highlighta">Pediatrics  </p>
<p class="Highlighta"> (= 40 kg)      </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">   1 mo. to 12 yrs     </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">0.1 mg/kg x 1  </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">over 2 to 5 min  </p></td>
</tr>
</tbody></table>
<ul><li>  In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, a total daily dose of 8 mg should not be exceeded. (<a href="#f3b1aff8-6bf7-4a0b-8385-b577b8f5de15">2.4</a>) </li></ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Ondansetron injection (2 mg/mL): 2 mL single dose vials and 20 mL multiple dose vials. (<a href="#e11fc598-578c-44cd-afb0-429d11c7e9b7">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Patients known to have <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to this product or any of its components. (<a href="#e11fc598-578c-44cd-afb0-429d11c7e9b7">4</a>)</li>
<li>Concomitant use of apomorphine. (<a href="#e72ba87f-088a-4b1a-afee-6afd111bbcc9">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, have been reported in patients who have exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other selective 5-HT<span class="Sub">3</span> receptor antagonists. (<a href="#e72ba87f-088a-4b1a-afee-6afd111bbcc9">5.1</a>)</li>
<li>QT prolongation occurs in a dose-dependent manner. Cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span> have been reported. Avoid ondansetron injection in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>. (<a href="#e72ba87f-088a-4b1a-afee-6afd111bbcc9">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> has been reported with 5-HT<span class="Sub">3</span> receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (<a href="#be1c1030-f5a0-4094-a8bf-25ced9e8dc70">5.3</a>) </li>
<li>Use in patients following abdominal surgery or in patients with chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may mask a progressive <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> and/or gastric <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>. (<a href="#fc77c777-f8d8-40da-8b19-23936117d26a">5.4</a>, <a href="#eb2667c2-7868-4dbb-a6ce-e0906d98c766">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> - </p>
<ul><li>The most common adverse reactions (≥ 7%) in adults are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. (<a href="#e72ba87f-088a-4b1a-afee-6afd111bbcc9">6.1</a>)</li></ul>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> - </p>
<ul>
<li>The most common adverse reaction (≥ 10%) which occurs at a higher frequency compared to placebo in adults is <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (<a href="#d9713a62-b527-4821-b0be-8b1f2de2ca0d">6.1</a>)</li>
<li>The most common adverse reaction (≥ 2%) which occurs at a higher frequency compared to placebo in pediatric patients 1 to 24 months of age is <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (<a href="#d9713a62-b527-4821-b0be-8b1f2de2ca0d">6.1</a>)</li>
</ul>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC, Vigilance &amp; Medical Affairs at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li>Apomorphine – profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>.  Concomitant use with ondansetron is contraindicated. (<a href="#af8fd57e-f58d-4f5b-88db-344f0f6629c4">7.2</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy<br></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Initial and Repeat Courses of Emetogenic Chemotherapy<br></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Stability and Handling<br></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosage Adjustment for Patients with Impaired Hepatic Function<br></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span><br></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 QT Prolongation<br></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Masking of Progressive <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span> and Gastric Distension</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Effect on Peristalsis</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience<br></a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience<br></a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drugs Affecting Cytochrome P-450 Enzymes<br></a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Apomorphine</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Phenytoin, Carbamazepine, and Rifampin<br></a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Tramadol</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Serotonergic Drugs</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Chemotherapy</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Temazepam</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Alfentanil and Atracurium</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span><br></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br></a></h2>
<h2><a href="#section-14.2" class="toc">14.2 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br></a></h2>
<h2><a href="#section-14.3" class="toc">14.3 Prevention of Further <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br></a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="b6ddbf4a-9dfb-4e9d-9c5a-9437c17d81c8"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="34067-9">
<a name="aa47f2bf-0caa-4c04-97ed-c1d09cb0cfeb"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy<br>
</h2>
<p class="First">Ondansetron injection is indicated for the prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin <span class="Italics"><span class="Emphasis">[<a href="#f03947d0-101a-44f8-acb9-61463e270ebe">see Clinical Studies (14.1)</a>]</span></span>.</p>
<p>Ondansetron is approved for patients aged 6 months and older.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="b95ac3fd-b2b9-40b3-a818-91a9f7c0de31"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</h2>
<p class="First">Ondansetron injection is indicated for the prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.  As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> will occur postoperatively.  In patients in whom <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> must be avoided postoperatively, ondansetron injection is recommended even when the incidence of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> is low.  For patients who do not receive <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> ondansetron injection and experience <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> postoperatively, ondansetron injection may be given to prevent further episodes <span class="Italics"><span class="Emphasis">[<a href="#a16f0e60-d9b2-4683-a1aa-1a8654b14f5f">see Clinical Studies (14.3)</a>]</span></span>.</p>
<p>Ondansetron is approved for patients aged 1 month and older.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="c262e026-d9c0-42c3-bc5b-088e6cafcbb8"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="e72c29fa-abca-419d-bac6-56c488c15704"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Initial and Repeat Courses of Emetogenic Chemotherapy<br>
</h2>
<p class="First">Ondansetron injection should be diluted in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection before administration.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline">Adults</span>:</span></span></p>
<p>The recommended adult intravenous dosage of ondansetron is three 0.15 mg/kg doses up to a maximum of 16 mg per dose [<span class="Italics"><span class="Emphasis">see <a href="#eeea82e4-909e-4311-a954-fece890a2d4c">Clinical Pharmacology (12.2)</a></span></span>].  The first dose is infused over 15 minutes beginning 30 minutes before the start of emetogenic chemotherapy.  Subsequent doses (0.15 mg/kg up to a maximum of 16 mg per dose) are administered 4 and 8 hours after the first dose of ondansetron.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline">Pediatrics</span>:</span></span></p>
<p>For pediatric patients 6 months through 18 years of age, the intravenous dosage of ondansetron is three 0.15 mg/kg doses up to a maximum of 16 mg per dose <span class="Italics"><span class="Emphasis">[see <a href="#f03947d0-101a-44f8-acb9-61463e270ebe">Clinical Studies (14.1)</a> and <a href="#f43121e7-39ba-4d82-a07a-327f7babf3a8">Clinical Pharmacology</a> (<a href="#eeea82e4-909e-4311-a954-fece890a2d4c">12.2</a>, <a href="#ba088515-171a-40d3-9397-1644c1932c0b">12.3</a>)]</span></span>.  The first dose is to be administered 30 minutes before the start of moderately to highly emetogenic chemotherapy.  Subsequent doses (0.15 mg/kg up to a maximum of 16 mg per dose) are administered 4 and 8 hours after the first dose of ondansetron.  The drug should be infused intravenously over 15 minutes.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f3b1aff8-6bf7-4a0b-8385-b577b8f5de15"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</h2>
<p class="First">Ondansetron injection should not be mixed with solutions for which physical and chemical compatibility have not been established.  In particular, this applies to alkaline solutions as a precipitate may form.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline">Adults</span>:</span></span></p>
<p>The recommended adult intravenous dosage of ondansetron is 4 mg <span class="Italics"><span class="Emphasis">undiluted</span></span> administered intravenously in not less than 30 seconds, preferably over 2 to 5 minutes, immediately before induction of anesthesia, or postoperatively if the patient did not receive <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> antiemetics and experiences <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurring within 2 hours after surgery.  Alternatively, 4 mg <span class="Italics"><span class="Emphasis">undiluted</span></span> may be administered intramuscularly as a single injection for adults.  While recommended as a fixed dose for patients weighing more than 40 kg, few patients above 80 kg have been studied.  In patients who do not achieve adequate control of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> following a single, <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span>, preinduction, intravenous dose of ondansetron 4 mg, administration of a second intravenous dose of 4 mg ondansetron postoperatively does not provide additional control of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline">Pediatrics</span>:</span></span></p>
<p>For pediatric patients 1 month through 12 years of age, the dosage is a single 0.1 mg/kg dose for patients weighing 40 kg or less, or a single 4 mg dose for patients weighing more than 40 kg.  The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes immediately prior to or following anesthesia induction, or postoperatively if the patient did not receive <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> antiemetics and experiences <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurring shortly after surgery.  Prevention of further <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> was only studied in patients who had not received <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> ondansetron.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b811fcc7-027e-47f3-a3b2-206d586def43"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Stability and Handling<br>
</h2>
<p class="First">After dilution, do not use beyond 24 hours.  Although ondansetron injection is chemically and physically stable when diluted as recommended, sterile precautions should be observed because diluents generally do not contain preservative.</p>
<p>Ondansetron injection is stable at room temperature under normal lighting conditions for 48 hours after dilution with the following intravenous fluids: 0.9% Sodium Chloride Injection, 5% Dextrose Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, 5% Dextrose and 0.45% Sodium Chloride Injection, and 3% Sodium Chloride Injection.</p>
<p><span class="Italics"><span class="Emphasis">Note:</span></span> Parenteral drug products should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit.</p>
<p><span class="Italics"><span class="Emphasis">Precaution:</span></span> Occasionally, ondansetron precipitates at the stopper/vial interface in vials stored upright.  Potency and safety are not affected.  If a precipitate is observed, resolubilize by <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> the vial vigorously.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ce5063c1-263b-4371-9218-6b4ff47a9139"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosage Adjustment for Patients with Impaired Hepatic Function<br>
</h2>
<p class="First">In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of 10 or greater), a single maximal daily dose of 8 mg infused over 15 minutes beginning 30 minutes before the start of the emetogenic chemotherapy is recommended.  There is no experience beyond first-day administration of ondansetron in these patients <span class="Italics"><span class="Emphasis">[see <a href="#ba088515-171a-40d3-9397-1644c1932c0b">Clinical Pharmacology (12.3)</a>]</span></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="e11fc598-578c-44cd-afb0-429d11c7e9b7"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Ondansetron injection, 2 mg/mL is a clear, colorless, nonpyrogenic, sterile solution available as a 2 mL single dose vial and a 20 mL multiple dose vial.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="e72ba87f-088a-4b1a-afee-6afd111bbcc9"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Ondansetron injection is contraindicated for patients known to have <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to this product or any of its components.  <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> have been reported in patients taking ondansetron <span class="Italics"><span class="Emphasis">[see <a href="#d7f39d24-df94-42f0-af51-097d2a8007b1">Adverse Reactions (6.2)</a>]</span></span>.</p>
<p>The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> when apomorphine was administered with ondansetron.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="b456ee3b-e576-431e-84b3-2594334e480a"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="b648f57f-3684-4236-9ec9-56c02d1b5127"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span><br>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, have been reported in patients who have exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other selective 5-HT<span class="Sub">3</span> receptor antagonists.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="f5ed76f9-1c87-45ad-9297-a23ddc81c4b1"></a><a name="section-5.2"></a><p></p>
<h2>5.2 QT Prolongation<br>
</h2>
<p class="First">Ondansetron prolongs the QT interval in a dose-dependent manner <span class="Italics"><span class="Emphasis">[see <a href="#eeea82e4-909e-4311-a954-fece890a2d4c">Clinical Pharmacology (12.2)</a>]</span></span>.  In addition, postmarketing cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span> have been reported in patients using ondansetron.  Avoid ondansetron in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>.  ECG monitoring is recommended in patients with electrolyte abnormalities (e.g., <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>), <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span>, or patients taking other medicinal products that lead to QT prolongation.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="be1c1030-f5a0-4094-a8bf-25ced9e8dc70"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">The development of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> has been reported with 5-HT<span class="Sub">3</span> receptor  antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors  (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). Some of the reported cases were fatal. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> occurring with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of ondansetron alone has also been reported. The majority of reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> related to 5-HT<span class="Sub">3</span> receptor antagonist use occurred in a post-anesthesia care unit or an infusion center. </p>
<p>Symptoms associated with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may include the following combination of signs and symptoms: <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular symptoms (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, with or without <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). Patients should be monitored for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, especially with concomitant use of ondansetron and other serotonergic drugs. If symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> occur, discontinue ondansetron and initiate supportive treatment. Patients should be informed of the increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, especially if ondansetron is used concomitantly with other serotonergic drugs <span class="Italics"><span class="Emphasis">[see <a href="#de5e3941-896b-4e0e-89b0-e21958c28837">Drug Interactions (7.5), </a><a href="#b4b9853d-3de7-4bea-af2f-4359e89ca715">Overdosage (10)</a> and <a href="#c40bda86-6116-4bd3-bbff-ab867c9896bb">Patient Counseling Information (17)</a></span></span><span class="Italics"><span class="Emphasis">]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="fc77c777-f8d8-40da-8b19-23936117d26a"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Masking of Progressive <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span> and Gastric Distension</h2>
<p class="First">The use of ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may mask a progressive <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> and gastric <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="eb2667c2-7868-4dbb-a6ce-e0906d98c766"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Effect on Peristalsis</h2>
<p class="First">Ondansetron is not a drug that stimulates gastric or intestinal peristalsis.  It should not be used instead of nasogastric suction.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d213870b-26d1-44f0-ab57-8c299e1a2b7c"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="d9713a62-b527-4821-b0be-8b1f2de2ca0d"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience<br>
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The following adverse reactions have been reported in clinical trials of adult patients treated with ondansetron, the active ingredient of intravenous ondansetron across a range of dosages.  A causal relationship to therapy with ondansetron was unclear in many cases.</p>
<p> </p>
<span class="Underline"><span class="Emphasis">Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>: </span></span><p> </p>
<p><span class="Bold"><span class="Emphasis">Table 1: </span></span><span class="Bold"><span class="Emphasis">Adverse Reactions Reported in &gt; 5% of Adult Patients Who </span></span></p>
<p><span class="Bold"><span class="Emphasis">     Received </span></span><span class="Bold"><span class="Emphasis">Ondansetron at a Dosage of Three 0.15 mg/kg Doses</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><p class="First">Adverse Reaction</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">Number of Adult Patients with Reaction</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Ondansetron Injection</p>
<p>0.15 mg/kg x 3</p>
<p>n = 419</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">  Metoclopramide   </p>
<p>n = 156</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">   Placebo   </p>
<p>n = 34</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">16%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">44%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">17%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">8%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3%</p></td>
</tr>
</tbody></table>
<p><span class="Italics"><span class="Emphasis">Cardiovascular:</span></span> Rare cases of angina (<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>), electrocardiographic alterations, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> have been reported.<br>
     <br><span class="Italics"><span class="Emphasis">Gastrointestinal:</span></span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> has been reported in 11% of chemotherapy patients receiving multiday ondansetron.<br>
     <br><span class="Italics"><span class="Emphasis">Hepatic:</span></span> In comparative trials in cisplatin chemotherapy patients with normal baseline values of aspartate transaminase (AST) and alanine transaminase (ALT), these enzymes have been reported to exceed twice the upper limit of normal in approximately 5% of patients.  The increases were transient and did not appear to be related to dose or duration of therapy.  On repeat exposure, similar transient elevations in transaminase values occurred in some courses, but symptomatic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> did not occur.<br>
     <br><span class="Italics"><span class="Emphasis">Integumentary:</span></span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> has occurred in approximately 1% of patients receiving ondansetron.<br>
     <br><span class="Italics"><span class="Emphasis">Neurological:</span></span> There have been rare reports consistent with, but not diagnostic of, extrapyramidal reactions in patients receiving ondansetron injection, and rare cases of <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal seizure</span>.<br>
     <br><span class="Italics"><span class="Emphasis">Other:</span></span> Rare cases of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> have been reported.<br>
     <br><span class="Underline"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></span></span>:</p>
<p>The adverse reactions in Table 2 have been reported in ≥ 2% of adults receiving ondansetron at a dosage of 4 mg intravenous over 2 to 5 minutes in clinical trials. </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis"> Table 2: Adverse Reactions Reported in ≥ 2% </span></span><span class="Bold"><span class="Emphasis">(and with Greater </span></span></p>
<p><span class="Bold"><span class="Emphasis">  Frequency than the Placebo Group) </span></span><span class="Bold"><span class="Emphasis">of Adult Patients Receiving </span></span></p>
<p><span class="Bold"><span class="Emphasis">  Ondansetron at a Dosage of 4 mg Intravenous  over 2 to 5 Minutes</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Adverse Reaction <span class="Sup">a,b</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">      Ondansetron Injection        </p>
<p>4 mg Intravenous</p>
<p>n = 547 patients</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Placebo</p>
<p>  n = 547 patients   </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">92 (17%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">77 (14%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>/sedation</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">44 (8%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">37 (7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">21 (4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18 (3%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">10 (2%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6 (1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">Cold</span> sensation</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">9 (2%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">8 (1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">9 (2%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">   3 (&lt; 1%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">9 (2%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">  2 (&lt; 1%)</p></td>
</tr>
</tbody></table>
<p><span class="Sup">a </span>Adverse Reactions: Rates of these reactions were not significantly different in the ondansetron and  placebo groups </p>
<p><span class="Sup">b </span>Patients were receiving multiple concomitant perioperative and postoperative medications</p>
<p><span class="Italics"><span class="Emphasis">Pediatric Use:</span></span><br>
    Rates of adverse reactions were similar in both the ondansetron and placebo groups in pediatric patients receiving ondansetron (a single 0.1 mg/kg dose for pediatric patients weighing 40 kg or less, or 4 mg for pediatric patients weighing more than 40 kg) administered intravenously over at least 30 seconds.  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> was seen more frequently in patients taking ondansetron (2%) compared to placebo (&lt; 1%) in the 1 month to 24 month age group.  These patients were receiving multiple concomitant perioperative and postoperative medications.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d7f39d24-df94-42f0-af51-097d2a8007b1"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience<br>
</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of ondansetron.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  The reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to ondansetron.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline">Cardiovascular</span>:</span></span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> (including ventricular and <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">premature ventricular contractions</span>, and <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, electrocardiographic alterations (including second-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, QT/QTc interval prolongation, and <span class="product-label-link" type="condition" conceptid="4095285" conceptname="ST segment depression">ST segment depression</span>), <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.  Rarely and predominantly with intravenous ondansetron, transient ECG changes including QT/QTc interval prolongation have been reported <span class="Italics"><span class="Emphasis">[see <a href="#f5ed76f9-1c87-45ad-9297-a23ddc81c4b1">Warnings and Precautions (5.2)</a>]</span></span>.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline">General</span>:</span></span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>.  Rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, sometimes severe (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4256374" conceptname="Cardiorespiratory arrest">cardiopulmonary arrest</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span>) have also been reported.  A positive lymphocyte transformation test to ondansetron has been reported, which suggests immunologic sensitivity to ondansetron.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline">Hepatobiliary</span>:</span></span> Liver enzyme abnormalities have been reported.  <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported in patients with cancer receiving concurrent medications including potentially hepatotoxic cytotoxic chemotherapy and antibiotics.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline">Local Reactions</span>:</span></span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, and burning at site of injection.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline">Lower Respiratory</span>:</span></span> <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccups</span>.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline">Neurological</span>:</span></span> <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">Oculogyric crisis</span>, appearing alone, as well as with other <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span>.  Transient <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> during or shortly after intravenous infusion.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline">Skin</span>:</span></span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span>:</span></span> Cases of <span class="product-label-link" type="condition" conceptid="372627" conceptname="Transient visual loss">transient blindness</span>, predominantly during intravenous administration, have been reported.  These cases of <span class="product-label-link" type="condition" conceptid="372627" conceptname="Transient visual loss">transient blindness</span> were reported to resolve within a few minutes up to 48 hours.  Transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, in some cases associated with abnormalities of accommodation, have also been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="d4605367-e316-45cb-929b-e087115f76f1"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="a20664e2-1200-440b-8669-11dff701f116"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drugs Affecting Cytochrome P-450 Enzymes<br>
</h2>
<p class="First">Ondansetron does not appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver.  Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron <span class="Italics"><span class="Emphasis">[see <a href="#ba088515-171a-40d3-9397-1644c1932c0b">Clinical Pharmacology (12.3)</a>]</span></span>.  On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="af8fd57e-f58d-4f5b-88db-344f0f6629c4"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Apomorphine</h2>
<p class="First">Based on reports of profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> when apomorphine was administered with ondansetron, the concomitant use of apomorphine with ondansetron is contraindicated <span class="Italics"><span class="Emphasis">[see <a href="#e72ba87f-088a-4b1a-afee-6afd111bbcc9">Contraindications (4)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="be98d7dc-5def-49ed-8b09-2262c2bbf728"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Phenytoin, Carbamazepine, and Rifampin<br>
</h2>
<p class="First">In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.  However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs <span class="Italics"><span class="Emphasis">[see <a href="#ba088515-171a-40d3-9397-1644c1932c0b">Clinical Pharmacology (12.3)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="faf93e61-9d56-4b4e-b476-2c05759f25a1"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Tramadol</h2>
<p class="First">Although there are no data on pharmacokinetic drug interactions between ondansetron and tramadol, data from two small studies indicate that concomitant use of ondansetron may result in reduced analgesic activity of tramadol.  Patients on concomitant ondansetron self administered tramadol more frequently in these studies, leading to an increased cumulative dose in patient controlled administration (PCA) of tramadol.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="de5e3941-896b-4e0e-89b0-e21958c28837"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Serotonergic Drugs</h2>
<p class="First">Serotinin syndrome (including altered mental status, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span>, and neuromuscular symptoms) has been described following the concomitant use of 5-HT<span class="Sub">3</span> receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) <span class="Italics"><span class="Emphasis">[see </span></span><span class="Italics"><span class="Emphasis"><a href="#be1c1030-f5a0-4094-a8bf-25ced9e8dc70">Warnings and Precautions (5.3)</a></span></span><span class="Italics"><span class="Emphasis">]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="d9152137-2732-45f2-af80-d1e1656b30f1"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Chemotherapy</h2>
<p class="First">In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.</p>
<p>In a crossover study in 76 pediatric patients, intravenous ondansetron did not increase blood levels of high-dose methotrexate.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ae8992ab-3e84-4000-9dfc-8aec74a7a8d3"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Temazepam</h2>
<p class="First">The coadministration of ondansetron had no effect on the pharmacokinetics and pharmacodynamics of temazepam.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="e4d02e72-cbc0-4692-b589-97456bf71949"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Alfentanil and Atracurium</h2>
<p class="First">Ondansetron does not alter the respiratory depressant effects produced by alfentanil or the degree of <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> produced by atracurium.  Interactions with general or local anesthetics have not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ece5ac8d-5ffc-4c94-8c33-6cc59c97156c"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="aaa26e2e-599b-41da-b535-a21e9db06366"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B. Reproduction studies have been performed in pregnant rats and rabbits at intravenous doses up to 4 mg/kg per day (approximately 1.4 and 2.9 times the recommended human intravenous dose of 0.15 mg/kg given three times a day, respectively, based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to ondansetron.  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="d3d10494-cc23-4340-981d-ddc9108292d9"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Ondansetron is excreted in the breast milk of rats.  It is not known whether ondansetron is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when ondansetron is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="c006f02f-0307-4f46-af5e-323197ef1951"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Little information is available about the use of ondansetron in pediatric surgical patients younger than 1 month of age <span class="Italics"><span class="Emphasis">[see <a href="#c63c88e0-12a7-450f-acf5-77e56534ab32">Clinical Studies (14.2)</a>]</span></span>.  Little information is available about the use of ondansetron in pediatric cancer patients younger than 6 months of age <span class="Italics"><span class="Emphasis">[see <a href="#f03947d0-101a-44f8-acb9-61463e270ebe">Clinical Studies (14.1)</a>  and <a href="#c262e026-d9c0-42c3-bc5b-088e6cafcbb8">Dosage and Administration (2)</a>]</span></span>.</p>
<p>The clearance of ondansetron in pediatric patients 1 month to 4 months of age is slower and the half-life is ~2.5 fold longer than patients who are &gt; 4 to 24 months of age.  As a precaution, it is recommended that patients less than 4 months of age receiving this drug be closely monitored <span class="Italics"><span class="Emphasis">[see <a href="#ba088515-171a-40d3-9397-1644c1932c0b">Clinical Pharmacology (12.3)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="fd294fba-89f6-48df-8962-a02a27438d79"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects enrolled in cancer chemotherapy-induced and <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in US- and foreign-controlled clinical trials, 862 were 65 years of age and over.  No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.  Dosage adjustment is not needed in patients over the age of 65 <span class="Italics"><span class="Emphasis">[see <a href="#ba088515-171a-40d3-9397-1644c1932c0b">Clinical Pharmacology (12.3)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="fbc6bef6-ed8e-4a28-8bcd-d96e2093f993"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span><br>
</h2>
<p class="First">In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of 10 or greater), clearance is reduced and apparent volume of distribution is increased with a resultant increase in plasma half-life <span class="Italics"><span class="Emphasis">[see <a href="#ba088515-171a-40d3-9397-1644c1932c0b">Clinical Pharmacology (12.3)</a>]</span></span>.  In such patients, a total daily dose of 8 mg should not be exceeded <span class="Italics"><span class="Emphasis">[see <a href="#b811fcc7-027e-47f3-a3b2-206d586def43">Dosage and Administration (2.3)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="a654285f-cb47-4d3f-9b2c-f8b041fdd86f"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br>
</h2>
<p class="First">Although plasma clearance is reduced in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt; 30 mL/min), no dosage adjustment is recommended <span class="Italics"><span class="Emphasis">[see <a href="#ba088515-171a-40d3-9397-1644c1932c0b">Clinical Pharmacology (12.3)</a>]</span></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="cb648086-6db1-4714-a128-8ad3d520e5a7"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Animal studies have shown that ondansetron is not discriminated as a benzodiazepine nor does it substitute for benzodiazepines in direct addiction studies.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="b4b9853d-3de7-4bea-af2f-4359e89ca715"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no specific antidote for ondansetron <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  Patients should be managed with appropriate supportive therapy.  Individual intravenous doses as large as 150 mg and total daily intravenous doses as large as 252 mg have been inadvertently administered without significant adverse events.  These doses are more than 10 times the recommended daily dose.</p>
<p>In addition to the adverse reactions listed above, the following events have been described in the setting of ondansetron <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>: “Sudden blindness? (<span class="product-label-link" type="condition" conceptid="4290687" conceptname="Amaurosis">amaurosis</span>) of 2 to 3 minutes’ duration plus severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> occurred in one patient that was administered 72 mg of ondansetron intravenously as a single dose.  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> (and faintness) occurred in another patient that took 48 mg of oral ondansetron.  Following infusion of 32 mg over only a 4-minute period, a vasovagal episode with transient second-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> was observed.  In all instances, the events resolved completely.</p>
<p>Pediatric cases consistent with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported after inadvertent oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of ondansetron (exceeding estimated ingestion of 5 mg/kg) in young children. Reported symptoms included <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, myoclonic movements, horizontal <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. Patients required supportive care, including intubation in some cases, with complete recovery without sequelae within 1 to 2 days.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="e0f8b66e-cbc0-4fd2-b7fa-0f9b1e3ec707"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">The active ingredient of Ondansetron Injection, USP is ondansetron hydrochloride, the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT<span class="Sub">3</span> receptor type.  Chemically it is (±) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1<span class="Italics"><span class="Emphasis">H</span></span>-imidazol-1-yl)methyl]-4<span class="Italics"><span class="Emphasis">H</span></span>-carbazol-4-one, monohydrochloride dihydrate.  It has the following structural formula:</p>
<p><img alt="ondansetron" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e0050959-c14c-41b6-9a92-fadc5f6feff3&amp;name=ondansetron-injection-usp-figure-1-ond-struct.jpg"> </p>
<p>Ondansetron is a white to off-white powder that is sparingly soluble in water. <br>
     <br>
    Each mL of the <span class="Bold"><span class="Emphasis">preservative-free </span></span>aqueous solution in the 2 mL single dose vial contains 2 mg of ondansetron as the hydrochloride; 9 mg of sodium chloride; and 0.5 mg of citric acid monohydrate and 0.25 mg of sodium citrate dihydrate as buffers in water for injection.<br>
     <br>
    Each mL of the <span class="Bold"><span class="Emphasis">preserved</span></span> aqueous solution in the 20 mL multiple dose vial contains 2 mg of ondansetron as the hydrochloride; 8.3 mg of sodium chloride; 0.5 mg of citric acid monohydrate and 0.25 mg of sodium citrate dihydrate as buffers; and 1.2 mg of methylparaben and 0.15 mg of propylparaben as preservatives in water for injection.<br>
     <br>
    Ondansetron Injection is a clear, colorless, nonpyrogenic, sterile solution for intravenous use.  The pH of the injection solution is 3.3 to 4.0.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="f43121e7-39ba-4d82-a07a-327f7babf3a8"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="bdc63c8f-f912-4430-90a9-1981097de156"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Ondansetron is a selective 5-HT<span class="Sub">3</span> receptor antagonist.  While ondansetron’s mechanism of action has not been fully characterized, it is not a dopamine-receptor antagonist.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="eeea82e4-909e-4311-a954-fece890a2d4c"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">QTc interval prolongation was studied in a double blind, single intravenous dose, placebo- and positive-controlled, crossover study in 58 healthy subjects. The maximum mean (95% upper confidence bound) difference in QTcF from placebo after baseline-correction was 19.5 (21.8) ms and 5.6 (7.4) ms after 15 minute intravenous infusions of 32 mg and 8 mg ondansetron, respectively. A significant exposure-response relationship was identified between ondansetron concentration and ΔΔQTcF. Using the established exposure-response relationship, 24 mg infused intravenously over 15 min had a mean predicted (95% upper prediction interval) ΔΔQTcF of 14 (16.3) ms. In contrast, 16 mg infused intravenously over 15 min using the same model had a mean predicted (95% upper prediction interval) ΔΔQTcF of 9.1 (11.2) ms.</p>
<p>In normal volunteers, single intravenous doses of 0.15 mg/kg of ondansetron had no effect on esophageal motility, gastric motility, lower esophageal sphincter pressure, or small intestinal transit time.  In another study in six normal male volunteers, a 16 mg dose infused over 5 minutes showed no effect of the drug on <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, heart rate, <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span>, blood pressure, or electrocardiogram (ECG).  Multiday administration of ondansetron has been shown to slow colonic transit in normal volunteers.  Ondansetron has no effect on plasma prolactin concentrations.  In a gender-balanced pharmacodynamic study (n = 56), ondansetron 4 mg administered intravenously or intramuscularly was dynamically similar in the prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> using the ipecacuanha model of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ba088515-171a-40d3-9397-1644c1932c0b"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">In normal adult volunteers, the following mean pharmacokinetic data have been determined following a single 0.15 mg/kg intravenous dose.</p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">                                                Table 3: Pharmacokinetics in Normal Adult Volunteers   </span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">  Age-group (years)  </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">  n   </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">  Peak Plasma Concentration   </p>
<p>(ng/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>  Mean Elimination </p>
<p>      Half-Life (h)     </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>  Plasma Clearance (L/h/kg)  </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>19 to 40</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>11</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>102</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>3.5</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>0.381</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>61 to 74</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>12</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>106</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>4.7</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>0.319</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>≥ 75</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>11</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>170</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>5.5</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>0.262</p>
</td>
</tr>
</tbody></table>
<br><p><span class="Underline"><span class="Emphasis"><span class="Bold">Absorption</span></span></span>:  A study was performed in normal volunteers (n = 56) to evaluate the pharmacokinetics of a single 4 mg dose administered as a 5 minute infusion compared to a single intramuscular injection.  Systemic exposure as measured by mean AUC were equivalent, with values of 156 [95% CI 136, 180] and 161 [95% CI 137, 190] ng•h/mL for intravenous and intramuscular groups, respectively.  Mean peak plasma concentrations were 42.9 [95% CI 33.8, 54.4] ng/mL at 10 minutes after intravenous infusion and 31.9 [95% CI 26.3, 38.6] ng/mL at 41 minutes after intramuscular injection.<br>
     <br><span class="Underline"><span class="Emphasis"><span class="Bold">Distribution</span></span></span>:  Plasma protein binding of ondansetron as measured <span class="Italics"><span class="Emphasis">in vitro</span></span> was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.  Circulating drug also distributes into erythrocytes.<br>
     <br><span class="Underline"><span class="Emphasis"><span class="Bold">Metabolism</span></span></span>:  Ondansetron is extensively metabolized in humans, with approximately 5% of a radiolabeled dose recovered as the parent compound from the urine.  The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation.<br>
     <br>
    Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron.  The metabolites are observed in the urine.  <br>
     <br><span class="Italics"><span class="Emphasis">In vitro</span></span> metabolism studies have shown that ondansetron is a substrate for multiple human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4.  In terms of overall ondansetron turnover, CYP3A4 plays a predominant role while formation of the major <span class="Italics"><span class="Emphasis">in vivo</span></span> metabolites is apparently mediated by CYP1A2.  The role of CYP2D6 in ondansetron <span class="Italics"><span class="Emphasis">in vivo</span></span> metabolism is relatively minor.<br>
     <br>
    The pharmacokinetics of intravenous ondansetron did not differ between subjects who were poor metabolizers of CYP2D6 and those who were extensive metabolizers of CYP2D6, further supporting the limited role of CYP2D6 in ondansetron disposition <span class="Italics"><span class="Emphasis">in vivo</span></span>.<br>
     <br><span class="Underline"><span class="Emphasis"><span class="Bold">Elimination</span></span></span>:  In adult cancer patients, the mean ondansetron elimination half-life was 4 hours, and there was no difference in the multiple dose pharmacokinetics over a 4 day period.  In a dose proportionality study, systemic exposure to 32 mg of ondansetron was not proportional to dose as measured by comparing dose-normalized AUC values to an 8 mg dose. This is consistent with a small decrease in systemic clearance with increasing plasma concentrations.</p>
<p><span class="Underline"><span class="Emphasis"><span class="Bold">Geriatrics</span></span></span>:  A reduction in clearance and increase in elimination half-life are seen in patients over 75 years of age.  In clinical trials with cancer patients, safety and efficacy were similar in patients over 65 years of age and those under 65 years of age; there was an insufficient number of patients over 75 years of age to permit conclusions in that age-group.  No dosage adjustment is recommended in the elderly.<br>
     <br><span class="Underline"><span class="Emphasis"><span class="Bold">Pediatrics</span></span></span>:  Pharmacokinetic samples were collected from 74 cancer patients 6 to 48 months of age, who received a dose of 0.15 mg/kg of intravenous ondansetron every 4 hours for 3 doses during a safety and efficacy trial.  These data were combined with sequential pharmacokinetics data from 41 surgery patients 1 month to 24 months of age, who received a single dose of 0.1 mg/kg of intravenous ondansetron prior to surgery with general anesthesia, and a population pharmacokinetic analysis was performed on the combined data set.  The results of this analysis are included in Table 4 and are compared to the pharmacokinetic results in cancer patients 4 to 18 years of age.</p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">            Table 4: Pharmacokinetics in Pediatric Cancer Patients </span></span></p>
<p><span class="Bold"><span class="Emphasis">                                  1 Month to 18 Years of Age</span></span> </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First">Subjects and Age Group </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">N </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">CL </p>
<p>  (L/h/kg)   </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Vd<span class="Sub">ss</span> </p>
<p>  (L/kg)  </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">T<span class="Sub">1/2</span> </p>
<p>(h) </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">  Geometric Mean   </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">  Mean   </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Pediatric Cancer Patients </p>
<p>4 to 18 years of age </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">N = 21 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.599 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1.9 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2.8 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Population PK Patients<span class="Sup">a</span> </p>
<p>1 month to 48 months of age     </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">  N = 115   </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.582 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3.65 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4.9 </p></td>
</tr>
</tbody></table>
<p><span class="Sup">a </span>Population PK (Pharmacokinetic) Patients: 64% cancer patients and 36% surgery patients. </p>
<p> </p>
<p>Based on the population pharmacokinetic analysis, cancer patients 6 to 48 months of age who receive a dose of 0.15 mg/kg of intravenous ondansetron every 4 hours for 3 doses would be expected to achieve a systemic exposure (AUC) consistent with the exposure achieved in previous pediatric studies in cancer patients (4 to 18 years of age) at similar doses.<br>
     <br>
    In a study of 21 pediatric patients (3 to 12 years of age) who were undergoing surgery requiring anesthesia for a duration of 45 minutes to 2 hours, a single intravenous dose of ondansetron, 2 mg (3 to 7 years) or 4 mg (8 to 12 years), was administered immediately prior to anesthesia induction.  Mean weight-normalized clearance and volume of distribution values in these pediatric surgical patients were similar to those previously reported for young adults.  Mean terminal half-life was slightly reduced in pediatric patients (range, 2.5 to 3 hours) in comparison with adults (range, 3 to 3.5 hours).<br>
     <br>
    In a study of 51 pediatric patients (1 month to 24 months of age) who were undergoing surgery requiring general anesthesia, a single intravenous dose of ondansetron, 0.1 or 0.2 mg/kg, was administered prior to surgery.  As shown in Table 5, the 41 patients with pharmacokinetic data were divided into 2 groups, patients 1 month to 4 months of age and patients 5 to 24 months of age, and are compared to pediatric patients 3 to 12 years of age.<br>
      </p>
<p><span class="Bold"><span class="Emphasis">Table 5: Pharmacokinetics in Pediatric Surgery Patients  </span></span></p>
<p><span class="Bold"><span class="Emphasis">                        1 Month to 12 Years of Age</span></span> </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First">Subjects and Age Group </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">N </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">CL </p>
<p>(L/h/kg) </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Vd<span class="Sub">ss</span> </p>
<p>(L/kg) </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">T<span class="Sub">1/2</span></p>
<p> (h) </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">Geometric Mean</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Mean </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Pediatric Surgery Patients </p>
<p>3 to 12 years of age </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">N = 21 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.439 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1.65 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2.9 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Pediatric Surgery Patients </p>
<p>5 to 24 months of age </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">N = 22 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.581 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2.3 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2.9 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Pediatric Surgery Patients </p>
<p>1 month to 4 months of age </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">N = 19 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.401 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3.5 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6.7 </p></td>
</tr>
</tbody></table>
<p>In general, surgical and cancer pediatric patients younger than 18 years tend to have a higher ondansetron clearance compared to adults leading to a shorter half-life in most pediatric patients.  In patients 1 month to 4 months of age, a longer half-life was observed due to the higher volume of distribution in this age group.</p>
<p>In a study of 21 pediatric cancer patients (4 to 18 years of age) who received three intravenous doses of 0.15 mg/kg of ondansetron at 4 hour intervals, patients older than 15 years of age exhibited ondansetron pharmacokinetic parameters similar to those of adults.</p>
<p><span class="Underline"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></span>:  Due to the very small contribution (5%) of renal clearance to the overall clearance, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> was not expected to significantly influence the total clearance of ondansetron.  However, ondansetron mean plasma clearance was reduced by about 41% in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt; 30 mL/min).  This reduction in clearance is variable and was not consistent with an increase in half-life.  No reduction in dose or dosing frequency in these patients is warranted.</p>
<p><span class="Underline"><span class="Emphasis"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></span>:  In patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in those without <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of 10 or greater), clearance is reduced 2-fold to 3-fold and apparent volume of distribution is increased with a resultant increase in half-life to 20 hours.  In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, a total daily dose of 8 mg should not be exceeded.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="e351b984-903e-4624-8528-a7f2571c33d4"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="dddbdd5e-6596-4f10-9c9d-b9b4569e202d"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenic effects were not seen in 2-year studies in rats and mice with oral ondansetron doses up to 10 and 30 mg/kg per day, respectively (approximately 3.6 and 5.4 times the recommended human intravenous dose of 0.15 mg/kg given three times a day, based on body surface area).  Ondansetron was not mutagenic in standard tests for mutagenicity.</p>
<p>Oral administration of ondansetron up to 15 mg/kg per day (approximately 3.8 times the recommended human intravenous dose, based on body surface area) did not affect fertility or general reproductive performance of male and female rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="fc389fb5-da12-4036-aa11-51334728bbb4"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The clinical efficacy of ondansetron hydrochloride, the active ingredient of ondansetron, was assessed in clinical trials as described below.</p>
<div class="Section" data-sectionCode="34092-7">
<a name="f03947d0-101a-44f8-acb9-61463e270ebe"></a><a name="section-14.1"></a><p></p>
<h2>14.1 Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</h2>
<p class="First"><span class="Underline"><span class="Emphasis"><span class="Bold">Adults</span></span></span>:</p>
<p>In a double-blind study of three different dosing regimens of ondansetron injection, 0.015 mg/kg, 0.15 mg/kg, and 0.3 mg/kg, each given three times during the course of cancer chemotherapy, the 0.15 mg/kg dosing regimen was more effective than the 0.015 mg/kg dosing regimen.  The 0.3 mg/kg dosing regimen was not shown to be more effective than the 0.15 mg/kg dosing regimen.</p>
<p><span class="Italics"><span class="Emphasis">Cisplatin-Based Chemotherapy:</span></span></p>
<p>In a double-blind study in 28 patients, ondansetron injection (three 0.15 mg/kg doses) was significantly more effective than placebo in preventing <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> induced by cisplatin-based chemotherapy.  Therapeutic response was as shown in Table 6.</p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">Table 6: Theraputic Response in Prevention of Chemotherapy-Induced </span></span></p>
<p><span class="Bold"><span class="Emphasis">    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> in Single-Day Cisplatin Therapy<span class="Sup">a</span> in Adults</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">   Ondansetron Injection   </p>
<p>(0.15 mg/kg x 3)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Italics"><span class="Emphasis">   P </span></span>Value<span class="Sup">b   </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Number of patients</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Treatment response</p>
<p>   0 Emetic episodes</p>
<p>   1 to 2 Emetic episodes</p>
<p>   3 to 5 Emetic episodes</p>
<p>   More than 5 emetic</p>
<p>   episodes/rescued</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>2 (14%)</p>
<p>8 (57%)</p>
<p>2 (14%)</p>
<p> </p>
<p>2 (14%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>0 (0%)</p>
<p>0 (0%)</p>
<p>1 (7%)</p>
<p> </p>
<p>13 (93%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p> </p>
<p> </p>
<p> </p>
<p> </p>
<p>0.001</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Median number of</p>
<p>   emetic episodes</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>1.5</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>Undefined<span class="Sup">c</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Median time to first </p>
<p>  emetic episode (h)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>11.6</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>2.8</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>0.001</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Median <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </p>
<p>  scores (0 to 100)<span class="Sup"> d</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>3</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>59</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>0.034</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Global satisfaction </p>
<p>   with control of     </p>
<p>   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and </p>
<p>   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0 to 100)<span class="Sup">e</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p> </p>
<p> </p>
<p>96</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p> </p>
<p> </p>
<p>10.5</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p> </p>
<p> </p>
<p>0.009</p>
</td>
</tr>
</tbody></table>
<p><span class="Sup">a </span>Chemotherapy was high dose (100 and 120 mg/m<span class="Sup">2</span>; ondansetron injection n = 6, placebo n = 5) or moderate dose (50 and 80 mg/m<span class="Sup">2</span>; ondansetron injection n = 8, placebo n = 9).  Other chemotherapeutic agents included fluorouracil, doxorubicin, and cyclophosphamide.  There was no difference between treatments in the types of chemotherapy that would account for differences in response. </p>
<p><span class="Sup">b </span>Efficacy based on “all patients treated? analysis. </p>
<p><span class="Sup">c</span> Median undefined since at least 50% of the patients were rescued or had more than five emetic episodes. </p>
<p><span class="Sup">d</span> Visual analog scale assessment of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>: 0 = no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 100 = <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> as bad as it can be.  </p>
<p><span class="Sup">e</span> Visual analog scale assessment of satisfaction: 0 = not at all satisfied, 100 = totally satisfied. </p>
<p> </p>
<p>Ondansetron injection (0.15 mg/kg x 3 doses) was compared with metoclopramide (2 mg/kg x 6 doses) in a single-blind trial in 307 patients receiving cisplatin ≥ 100 mg/m<span class="Sup">2</span> with or without other chemotherapeutic agents.  Patients received the first dose of ondansetron or metoclopramide 30 minutes before cisplatin.  Two additional ondansetron doses were administered 4 and 8 hours later, or five additional metoclopramide doses were administered 2, 4, 7, 10, and 13 hours later.  Cisplatin was administered over a period of 3 hours or less.  Episodes of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4309379" conceptname="Retching">retching</span> were tabulated over the period of 24 hours after cisplatin.  The results of this study are summarized in Table 7. </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">                               Table 7: Therapeutic Response in Prevention of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Induced by </span></span></p>
<p><span class="Bold"><span class="Emphasis">                                        Cisplatin (≥ 100 mg/m</span></span><span class="Bold"><span class="Emphasis"><span class="Sup">2</span></span></span><span class="Bold"><span class="Emphasis">) Single-Day Therapy<span class="Sup">a</span> in Adults</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">   Ondansetron Injection   </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">    Metoclopramide   </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Italics"><span class="Emphasis">    P</span></span> Value     </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"> </p>
<p>Dose</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>0.15 mg/kg x 3</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>2 mg/kg x 6</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Number of patients in efficacy population</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">136</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">138</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Treatment response</p>
<p>   0 Emetic episodes</p>
<p>   1 to 2 Emetic episodes</p>
<p>   3 to 5 Emetic episodes</p>
<p>   More than 5 emetic episodes/rescued</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>54 (40%)</p>
<p>34 (25%)</p>
<p>19 (14%)</p>
<p>29 (21%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>41 (30%)</p>
<p>30 (22%)</p>
<p>18 (13%)</p>
<p>49 (36%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Comparison of treatments with respect to </p>
<p>   0 Emetic episodes</p>
<p>   More than 5 emetic episodes/rescued</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>54/136</p>
<p>29/136</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>41/138</p>
<p>49/138</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>0.083</p>
<p>0.009</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Median number of emetic episodes</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.005</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Median time to first emetic episode (h)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">20.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">&lt;0.001</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Global satisfaction with control of</p>
<p>   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0 to 100)<span class="Sup">b</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>85</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>63</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>0.001</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Acute <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.005</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.002</p></td>
</tr>
</tbody></table>
<p><span class="Sup">a </span>In addition to cisplatin, 68% of patients received other chemotherapeutic agents, including cyclophosphamide, etoposide, and fluorouracil.  There was no difference between treatments in the types of chemotherapy that would account for differences in response.</p>
<p><span class="Sup">b </span>Visual analog scale assessment: 0 = not at all satisfied, 100 = totally satisfied.  </p>
<p> </p>
<span class="Italics"><span class="Emphasis">Cyclophosphamide-Based Chemotherapy:</span></span><br><p>In a double-blind, placebo-controlled study of ondansetron injection (three 0.15 mg/kg doses) in 20 patients receiving cyclophosphamide (500 to 600 mg/m<span class="Sup">2</span>) chemotherapy, ondansetron injection was significantly more effective than placebo in preventing <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.  The results are summarized in Table 8. <br>
     </p>
<p><span class="Bold"><span class="Emphasis">Table 8: Therapeutic Response in Prevention of Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and</span></span></p>
<p><span class="Bold"><span class="Emphasis">                 <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> in Single-Day Cyclophosphamide Therapy<span class="Sup">a</span> in Adults</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">   Ondansetron Injection   </p>
<p>(0.15 mg/kg x 3)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>Placebo</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Italics"><span class="Emphasis">   P</span></span> Value<span class="Sup">b   </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Number of patients</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Treatment response</p>
<p>   0 Emetic episodes</p>
<p>   1 to 2 Emetic episodes</p>
<p>   3 to 5 Emetic episodes</p>
<p>  More than 5 emetic episodes/rescued</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>7 (70%)</p>
<p>   0 (0%)    </p>
<p>2 (20%)</p>
<p>1 (10%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>       0 (0%)        </p>
<p>2 (20%)</p>
<p>4 (40%)</p>
<p>4 (40%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>0.001</p>
<p> </p>
<p> </p>
<p>0.131</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Median number of emetic episodes</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.008</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Median time to first emetic episode (h)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Undefined<span class="Sup">c</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">8.79</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Median <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> scores (0 to 100)<span class="Sup"> d</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">60</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.001</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Global satisfaction with control of </p>
<p> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0 to 100)<span class="Sup"> e</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>100</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>52</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>0.008</p>
</td>
</tr>
</tbody></table>
<p><span class="Sup">a </span>Chemotherapy consisted of cyclophosphamide in all patients, plus other agents, including fluorouracil, doxorubicin, methotrexate, and vincristine.  There was no difference between treatments in the type of chemotherapy that would account for differences in response. </p>
<p><span class="Sup">b </span>Efficacy based on “all patients treated? analysis.</p>
<p><span class="Sup">c </span>Median undefined since at least 50% of patients did not have any emetic episodes.</p>
<p><span class="Sup">d </span>Visual analog scale assessment of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>: 0 = no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 100 = <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> as bad as it can be.  </p>
<p><span class="Sup">e</span> Visual analog scale assessment of satisfaction: 0 = not at all satisfied, 100 = totally satisfied.</p>
<p> </p>
<p><span class="Italics"><span class="Emphasis">Re-treatment:</span></span></p>
<p>In uncontrolled trials, 127 patients receiving cisplatin (median dose, 100 mg/m<span class="Sup">2</span>) and ondansetron who had two or fewer emetic episodes were re-treated with ondansetron and chemotherapy, mainly cisplatin, for a total of 269 re-treatment courses (median, 2; range, 1 to 10).  No emetic episodes occurred in 160 (59%), and two or fewer emetic episodes occurred in 217 (81%) re-treatment courses.</p>
<p> </p>
<p><span class="Underline"><span class="Emphasis"><span class="Bold">Pediatrics</span></span></span>:</p>
<p>Four open-label, noncomparative (one US, three foreign) trials have been performed with 209 pediatric cancer patients 4 to 18 years of age given a variety of cisplatin or noncisplatin regimens.  In the three foreign trials, the initial ondansetron injection dose ranged from 0.04 to 0.87 mg/kg for a total dose of 2.16 to 12 mg.  This was followed by the oral administration of ondansetron ranging from 4 to 24 mg daily for 3 days.  In the US trial, ondansetron was administered intravenously (only) in three doses of 0.15 mg/kg each for a total daily dose of 7.2 to 39 mg.  In these studies, 58% of the 196 evaluable patients had a complete response (no emetic episodes) on day 1.  Thus, prevention of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in these pediatric patients was essentially the same as for patients older than 18 years of age.</p>
<p>An open-label, multicenter, noncomparative trial has been performed in 75 pediatric cancer patients 6 to 48 months of age receiving at least one moderately or highly emetogenic chemotherapeutic agent.  Fifty-seven percent (57%) were females; 67% were white, 18% were American Hispanic, and 15% were black patients.  Ondansetron was administered intravenously over 15 minutes in three doses of 0.15 mg/kg.  The first dose was administered 30 minutes before the start of chemotherapy, the second and third doses were administered 4 and 8 hours after the first dose, respectively.  Eighteen patients (25%) received routine <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> dexamethasone (i.e., not given as rescue).  Of the 75 evaluable patients, 56% had a complete response (no emetic episodes) on day 1.  Thus, prevention of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in these pediatric patients was comparable to the prevention of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in patients 4 years of age and older.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="c63c88e0-12a7-450f-acf5-77e56534ab32"></a><a name="section-14.2"></a><p></p>
<h2>14.2 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</h2>
<p class="First"><span class="Underline"><span class="Emphasis"><span class="Bold">Adults</span></span></span>:</p>
<p>Adult surgical patients who received ondansetron immediately before the induction of general balanced anesthesia (barbiturate: thiopental, methohexital, or thiamylal; opioid: alfentanil or fentanyl; nitrous oxide; <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>: succinylcholine/curare and/or vecuronium or atracurium; and supplemental isoflurane) were evaluated in two double-blind US studies involving 554 patients.  Ondansetron injection (4 mg) intravenous given over 2 to 5 minutes was significantly more effective than placebo.  The results of these studies are summarized in Table 9.</p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">Table 9: Therapeutic Response in Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> in Adult Patients</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">   Ondansetron 4 mg Intravenous   </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">   Placebo   </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Italics"><span class="Emphasis">   P</span></span> Value    </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Study 1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Emetic episodes: </p>
<p>Number of patients</p>
<p>Treatment response over 24-h postoperative period</p>
<p>   0 Emetic episodes</p>
<p>   1 Emetic episode</p>
<p>   More than 1 emetic episode/rescued</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>136</p>
<p> </p>
<p> </p>
<p>103 (76%)</p>
<p>13 (10%)</p>
<p>20 (15%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>139</p>
<p> </p>
<p> </p>
<p>64 (46%)</p>
<p>17 (12%)</p>
<p>58 (42%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p> </p>
<p> </p>
<p>&lt; 0.001</p>
<p> </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> assessments:</p>
<p>Number of patients</p>
<p>No <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> over 24-h postoperative period</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>134</p>
<p>56 (42%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>136</p>
<p>39 (29%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Study 2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Emetic episodes:</p>
<p>Number of patients</p>
<p>Treatment response over 24-h postoperative period</p>
<p>   0 Emetic episodes</p>
<p>   1 Emetic episode</p>
<p>   More than 1 emetic episode/rescued</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>136</p>
<p> </p>
<p> </p>
<p>85 (63%)</p>
<p>16 (12%)</p>
<p>35 (26%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>143</p>
<p> </p>
<p> </p>
<p>63 (44%)</p>
<p>29 (20%)</p>
<p>51 (36%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p> </p>
<p> </p>
<p>0.002</p>
<p> </p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> assessments:</p>
<p>Number of patients</p>
<p>No <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> over 24-h postoperative period</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>125</p>
<p>48 (38%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>133</p>
<p>42 (32%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
</tbody></table>
<p>The study populations in Table 9 consisted mainly of females undergoing laparoscopic procedures.</p>
<p>In a placebo-controlled study conducted in 468 males undergoing outpatient procedures, a single 4 mg intravenous ondansetron dose prevented postoperative <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> over a 24-hour study period in 79% of males receiving drug compared to 63% of males receiving placebo (<span class="Italics"><span class="Emphasis">P</span></span> &lt;0.001).</p>
<p>Two other placebo-controlled studies were conducted in 2,792 patients undergoing major abdominal or gynecological surgeries to evaluate a single 4 mg or 8 mg intravenous ondansetron dose for prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> over a 24-hour study period.  At the 4 mg dosage, 59% of patients receiving ondansetron versus 45% receiving placebo in the first study (<span class="Italics"><span class="Emphasis">P</span></span>&lt;0.001) and 41% of patients receiving ondansetron versus 30% receiving placebo in the second study (<span class="Italics"><span class="Emphasis">P</span></span>=0.001) experienced no emetic episodes.  No additional benefit was observed in patients who received intravenous ondansetron 8 mg compared to patients who received intravenous ondansetron 4 mg.</p>
<p> </p>
<p><span class="Underline"><span class="Emphasis"><span class="Bold">Pediatrics</span></span></span>:</p>
<p>Three double-blind, placebo-controlled studies have been performed (one US, two foreign) in 1,049 male and female patients (2 to 12 years of age) undergoing general anesthesia with nitrous oxide.  The surgical procedures included tonsillectomy with or without adenoidectomy, <span class="product-label-link" type="condition" conceptid="4329707" conceptname="Strabismus">strabismus</span> surgery, herniorrhaphy, and orchidopexy.  Patients were randomized to either single intravenous doses of ondansetron (0.1 mg/kg for pediatric patients weighing 40 kg or less, 4 mg for pediatric patients weighing more than 40 kg) or placebo.  Study drug was administered over at least 30 seconds, immediately prior to or following anesthesia induction.  Ondansetron was significantly more effective than placebo in preventing <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>The results of these studies are summarized in Table 10. </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">Table 10: Therapeutic Response in Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span></span></span></p>
<p><span class="Bold"><span class="Emphasis">             and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> in Pediatric Patients 2 to 12 Years of Age</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First">Treatment Response Over 24 Hours</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Ondansetron </p>
<p>n (%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Placebo </p>
<p>n (%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First"><span class="Italics"><span class="Emphasis">P</span></span> Value</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Study 1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Number of patients</p>
<p>0 Emetic episodes</p>
<p>Failure<span class="Sup">a</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">205</p>
<p>140 (68%)</p>
<p>65 (32%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">210</p>
<p>82 (39%)</p>
<p>128 (61%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"> </p>
<p>≤ 0.001</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Study 2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Number of patients</p>
<p>0 Emetic episodes</p>
<p>Failure<span class="Sup">a</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">112</p>
<p>68 (61%)</p>
<p>44 (39%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">110</p>
<p>38 (35%)</p>
<p>72 (65%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"> </p>
<p>≤ 0.001</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Study 3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Number of patients</p>
<p>0 Emetic episodes</p>
<p>Failure<span class="Sup">a</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">206</p>
<p>123 (60%)</p>
<p>83 (40%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">206</p>
<p>96 (47%)</p>
<p>110 (53%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"> </p>
<p>≤ 0.01</p>
<p> </p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> assessments<span class="Sup">b</span>:</p>
<p>Number of patients</p>
<p>None</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>185</p>
<p>119 (64%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"> </p>
<p>191</p>
<p>99 (52%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"> </p>
<p> </p>
<p>≤ 0.01</p>
</td>
</tr>
</tbody></table>
<p><span class="Sup">a </span>Failure was one or more emetic episodes, rescued, or withdrawn.</p>
<p><span class="Sup">b </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> measured as none, mild, or severe.</p>
<p> </p>
<p>A double-blind, multicenter, placebo-controlled study was conducted in 670 pediatric patients 1 month to 24 months of age who were undergoing routine surgery under general anesthesia.  Seventy-five percent (75%) were males; 64% were white, 15% were black, 13% were American Hispanic, 2% were Asian, and 6% were “other race? patients.  A single 0.1 mg/kg intravenous dose of ondansetron administered within 5 minutes following induction of anesthesia was statistically significantly more effective than placebo in preventing <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. In the placebo group, 28% of patients experienced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> compared to 11% of subjects who received ondansetron (<span class="Italics"><span class="Emphasis">P </span></span>≤ 0.01).  Overall, 32 (10%) of placebo patients and 18 (5%) of patients who received ondansetron received antiemetic rescue medication(s) or prematurely withdrew from the study.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="a16f0e60-d9b2-4683-a1aa-1a8654b14f5f"></a><a name="section-14.3"></a><p></p>
<h2>14.3 Prevention of Further <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</h2>
<p class="First"><span class="Underline"><span class="Emphasis"><span class="Bold">Adults</span></span></span>:</p>
<p>Adult surgical patients receiving general balanced anesthesia (barbiturate: thiopental, methohexital, or thiamylal; opioid: alfentanil or fentanyl; nitrous oxide; <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>: succinylcholine/curare and/or vecuronium or atracurium; and supplemental isoflurane) who received no <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> antiemetics and who experienced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> within 2 hours postoperatively were evaluated in two double-blind US studies involving 441 patients.  Patients who experienced an episode of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> were given ondansetron injection (4 mg) intravenous over 2 to 5 minutes, and this was significantly more effective than placebo.  The results of these studies are summarized in Table 11.</p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">    Table 11: Therapeutic Response in Prevention of Further Postoperative</span></span></p>
<p><span class="Bold"><span class="Emphasis">                               <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> in Adult Patients</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Ondansetron</p>
<p>4 mg Intravenous</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Italics"><span class="Emphasis">P</span></span> Value</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First">Study 1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Emetic episodes:</p>
<p>Number of patients</p>
<p>Treatment response 24-h after study drug</p>
<p>   0 Emetic episodes</p>
<p>   1 Emetic episode</p>
<p>   More than 1 emetic episode/rescued</p>
<p>Median time to first emetic episode (min)<span class="Sup">a</span> </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>104</p>
<p> </p>
<p>49 (47%)</p>
<p>12 (12%)</p>
<p>43 (41%)</p>
<p>55</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>117</p>
<p> </p>
<p>19 (16%)</p>
<p>9 (8%)</p>
<p>89 (76%)</p>
<p>43</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p> </p>
<p> </p>
<p>&lt; 0.001</p>
<p> </p>
<p> </p>
<p> </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> assessments:</p>
<p>Number of patients</p>
<p>Mean <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> score over 24-h postoperative period<span class="Sup">b</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>98</p>
<p>1.7</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>102</p>
<p>3.1</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First">Study 2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Emetic episodes:</p>
<p>Number of patients</p>
<p>Treatment response 24-h after study drug</p>
<p>   0 Emetic episodes</p>
<p>   1 Emetic episode</p>
<p>   More than 1 emetic episode/rescued</p>
<p>Median time to first emetic episode (min)<span class="Sup">a</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>112</p>
<p> </p>
<p>49 (44%)</p>
<p>14 (13%)</p>
<p>49 (44%)</p>
<p>60.5</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>108</p>
<p> </p>
<p>28 (26%)</p>
<p>3 (3%)</p>
<p>77 (71%)</p>
<p>34</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p> </p>
<p> </p>
<p>0.006</p>
<p> </p>
<p> </p>
<p> </p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> assessments:</p>
<p>Number of patients</p>
<p>Mean <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> score over 24-h postoperative period<span class="Sup">b</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>105</p>
<p>1.9</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>85</p>
<p>2.9</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
</tbody></table>
<p><span class="Sup">a </span>After administration of study drug.  </p>
<p><span class="Sup">b </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> measured on a scale of 0 to 10 with 0 = no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 10 = <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> as bad as it can be. </p>
<p> </p>
<p>The study populations in Table 11 consisted mainly of women undergoing laparoscopic procedures.</p>
<p><span class="Italics"><span class="Emphasis">Repeat Dosing in Adults:</span></span></p>
<p>In patients who do not achieve adequate control of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> following a single, <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span>, preinduction, intravenous dose of ondansetron 4 mg, administration of a second intravenous dose of ondansetron 4 mg postoperatively does not provide additional control of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Underline"><span class="Emphasis"><span class="Bold">Pediatrics</span></span></span>:</p>
<p>One double-blind, placebo-controlled, US study was performed in 351 male and female outpatients (2 to 12 years of age) who received general anesthesia with nitrous oxide and no <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> antiemetics.  Surgical procedures were unrestricted.  Patients who experienced two or more emetic episodes within 2 hours following discontinuation of nitrous oxide were randomized to either single intravenous doses of ondansetron (0.1 mg/kg for pediatric patients weighing 40 kg or less, 4 mg for pediatric patients weighing more than 40 kg) or placebo administered over at least 30 seconds.  Ondansetron was significantly more effective than placebo in preventing further episodes of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.  The results of the study are summarized in Table 12.</p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">    Table 12: Therapeutic Response in Prevention </span></span></p>
<p><span class="Bold"><span class="Emphasis">     of Further <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </span></span></p>
<p><span class="Bold"><span class="Emphasis">        in Pediatric Patients 2 to 12 Years of Age</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Treatment Response</p>
<p>Over 24 Hours</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">  Ondansetron  </p>
<p>n (%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">  Placebo  </p>
<p>n (%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Italics"><span class="Emphasis">  P</span></span> Value   </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Number of patients</p>
<p>0 Emetic episodes</p>
<p>Failure<span class="Sup">a</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">180</p>
<p>96 (53%)</p>
<p>84 (47%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">171</p>
<p>29 (17%)</p>
<p>142 (83%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>≤ 0.001 </p>
<p> </p>
</td>
</tr>
</tbody></table>
<p><span class="Sup">a </span>Failure was one or more emetic episodes, rescued, or withdrawn.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="fd259d90-e6cc-484c-ae55-e32b9499fa4e"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Ondansetron Injection, USP, available as a single dose (<span class="Bold"><span class="Emphasis">preservative free</span></span>) vial, is supplied as follows: </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Product    </span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC </span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Strength</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Vial Size</span></span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">370302</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-373-02     </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 mg/mL       </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 mL fill, in a 2 mL vial, packaged in trays of 25.         </p></td>
</tr>
</tbody></table>
<p>Ondansetron Injection, USP, available as a multiple dose (<span class="Bold"><span class="Emphasis">preserved</span></span>) vial, is supplied as follows: </p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Product    </span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Strength      <br></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Vial Size</span></span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">370420</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-374-20     </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 mg/mL</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">20 mL fill, in a 20 mL vial, packaged individually.        </p></td>
</tr>
</tbody></table>
<p>Store between 2° to 25°C (36° to 77°F).  Protect from light.</p>
<p>This container closure is not made with natural rubber latex.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="c40bda86-6116-4bd3-bbff-ab867c9896bb"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<ul><li>Patients should be informed that ondansetron may cause serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> such as QT prolongation. Patients should be instructed to tell their health care provider right away if they perceive a change in their heart rate, if they feel lightheaded, or if they have a syncopal episode. </li></ul>
<ul><li>Patients should be informed that the chances of developing severe <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> such as QT prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span> are higher in the following people:
        <ul>
<li>Patients with a personal or family history of abnormal heart rhythms, such as congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>;</li>
<li>Patients who take medications, such as diuretics, which may cause electrolyte abnormalities</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> </li>
</ul>
</li></ul>
<p class="First">Ondansetron should be avoided in these patients, since they may be more at risk for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> such as QT prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span>.</p>
<ul>
<li>Advise patients of the possibility of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with concomitant use of ondansetron and another serotonergic agent such as medications to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and  <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>. Advise patients to seek immediate medical attention if the following symptoms occur: changes in mental status, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span>, neuromuscular symptoms with or without <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>. </li>
<li>Inform patients that ondansetron may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, some as severe as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.  The patient should report any signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or breathing problems.</li>
<li>The patient should report the use of all medications, especially apomorphine, to their healthcare provider.  Concomitant use of apomorphine and ondansetron may cause a significant <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>.</li>
<li>Inform patients that ondansetron may cause <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>/sedation, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</li>
</ul>
<p> </p>
<p><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e0050959-c14c-41b6-9a92-fadc5f6feff3&amp;name=ondansetron-injection-usp-figure-2-fk-address.jpg"> </p>
<p>451002F</p>
<p>Revised: October 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ebb05884-3e68-49b0-83ab-335db6351212"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold"><span class="Emphasis">- Ondansetron 2 mL Single Dose Vial Label</span></span></p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">NDC </span></span>63323-373-02</p>
<p>370302</p>
<p><span class="Bold"><span class="Emphasis">Ondansetron Injection, USP<br></span></span></p>
<p><span class="Bold"><span class="Emphasis">4 mg/2 mL (2 mg/mL)</span></span></p>
<p>For IM or IV Use</p>
<p>Rx only</p>
<p>Usual Dosage: See insert.</p>
<p><span class="Bold"><span class="Emphasis">2 mL </span></span>Single Dose Vial</p>
<span class="Bold"><span class="Emphasis"><br></span></span><p><span class="Bold"><span class="Emphasis"><img alt="vial 370302" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e0050959-c14c-41b6-9a92-fadc5f6feff3&amp;name=ondansetron-injection-usp-figure-3-370302-vial.jpg"></span></span><span class="Bold"><span class="Emphasis"><br></span></span></p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY</span></span></p>
<p><span class="Bold"><span class="Emphasis">- Ondansetron 2 mL Single Dose Vial Tray Label</span></span></p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">NDC </span></span>63323-373-02</p>
<p>370302</p>
<p><span class="Bold"><span class="Emphasis">Ondansetron Injection, USP<br></span></span></p>
<p><span class="Bold"><span class="Emphasis">4 mg/2 mL (2 mg/mL)</span></span></p>
<p>For IM or IV Use</p>
<p>Rx only</p>
<p><span class="Bold"><span class="Emphasis">2 mL </span></span>Single Dose Vial</p>
<p><img alt="tray 370302" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e0050959-c14c-41b6-9a92-fadc5f6feff3&amp;name=ondansetron-injection-usp-figure-4-370302-tray.jpg"> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY    <br></span></span></p>
<p><span class="Bold"><span class="Emphasis">- Ondansetron 20 mL Multiple Dose Vial Label <br>
     </span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC </span></span>63323-374-20</p>
<p>370420</p>
<p><span class="Bold"><span class="Emphasis">Ondansetron Injection, USP<br></span></span></p>
<p><span class="Bold"><span class="Emphasis">40 mg/20 mL (2 mg/mL)</span></span></p>
<p>For IM or IV Use</p>
<p>Rx only</p>
<p><span class="Bold"><span class="Emphasis">20 mL </span></span>Multiple Dose Vial</p>
<p> </p>
<p><span class="Bold"><span class="Emphasis"><img alt="vial 370420" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e0050959-c14c-41b6-9a92-fadc5f6feff3&amp;name=ondansetron-injection-usp-figure-5-370420-vial.jpg"></span></span></p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY </span></span></p>
<p><span class="Bold"><span class="Emphasis">- Ondansetron 20 mL Multiple Dose Vial Carton Panel <br></span></span></p>
<p><span class="Bold"><span class="Emphasis"><br></span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC </span></span>63323-374-20</p>
<p>370420</p>
<p><span class="Bold"><span class="Emphasis">Ondansetron Injection, USP<br></span></span></p>
<p><span class="Bold"><span class="Emphasis">40 mg/20 mL* (2 mg/mL)</span></span></p>
<p>For IM or IV Use</p>
<p>Rx only</p>
<p><span class="Bold"><span class="Emphasis">20 mL </span></span>Multiple Dose Vial</p>
<p> <img alt="370420" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e0050959-c14c-41b6-9a92-fadc5f6feff3&amp;name=ondansetron-injection-usp-figure-6-370420-pbox.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ONDANSETRON 		
					</strong><br><span class="contentTableReg">ondansetron hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-373</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ONDANSETRON HYDROCHLORIDE</strong> (ONDANSETRON) </td>
<td class="formItem">ONDANSETRON</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem">0.25 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-373-02</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076972</td>
<td class="formItem">11/18/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ONDANSETRON 		
					</strong><br><span class="contentTableReg">ondansetron hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-374</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ONDANSETRON HYDROCHLORIDE</strong> (ONDANSETRON) </td>
<td class="formItem">ONDANSETRON</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">8.3 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem">0.25 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">1.2 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">0.15 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-374-20</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076974</td>
<td class="formItem">11/18/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi USA, LLC</td>
<td class="formItem"></td>
<td class="formItem">840771732</td>
<td class="formItem">MANUFACTURE(63323-373, 63323-374)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e338df86-2858-4b13-ab02-d3541fa12d0e</div>
<div>Set id: e0050959-c14c-41b6-9a92-fadc5f6feff3</div>
<div>Version: 7</div>
<div>Effective Time: 20141126</div>
</div>
</div> <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
